Key facts
- Cellcolabs’s last known valuation is $59.0M (Mar 2024).
- It has raised $39.4M; the latest was Early Stage VC ($12.0M) in Oct 2025.
- Notable investors include Titan Capital, Unruly Capital, Norrsken VC, Fredrik Hjelm, Filip Engelbert — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cellcolabs
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellcolabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellcolabs
Developer of a biotech platform designed to advance a new paradigm in medicine. The company offers industrial GMP (Good Manufacturing Practice) production of stem cells (mesenchymal stromal cells) to make them available at scale, enabling healthcare providers to accelerate stem cell research and expand access to future treatments.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2021
- Employees
- 80
- Website
- cellcolabs.com/
- Ownership
- Privately Held (backing)
Cellcolabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellcolabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellcolabs in its N-PORT filings yet. We sweep new filings monthly.